Radiopharmaceuticals in the Treatment of Metastatic Castration-Resistant Prostate Cancer

In this episode, Chris Parker, MD, and Bertrand Tombal, MD, PhD, discuss the clinical implications of the latest data on radiopharmaceuticals in the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). Topics include:

• Data from the PEACE-3 trial on the effect of bone-protective agents on fracture risk with enzalutamide plus radium-223
• Efficacy and toxicity of PSMA lutetium plus standard of care in the VISION trial
• Ongoing trials evaluating radionuclides in combination with other agents in metastatic CRPC

Presenters:

Chris Parker, MD
Professor of Prostate Oncology
Institute of Cancer Research
Clinical Oncologist
Department of Uro-oncology
Royal Marsden Hospital
Sutton, Surrey, United Kingdom

Bertrand Tombal, MD, PhD
Professor of Urology
Institut de Recherche Clinique (IRC)
Cliniques universitaires Saint-Luc
Chairman
Department of Surgery
Cliniques universitaires Saint-Luc
Brussels, Belgium

Link to full program, including downloadable slides: 
https://bit.ly/36IEnNE